These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 31740561)
21. Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention. Nicol MR; Corbino JA; Cottrell ML J Clin Pharmacol; 2018 Nov; 58(11):1381-1395. PubMed ID: 29901863 [TBL] [Abstract][Full Text] [Related]
22. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients. Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L; J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606 [TBL] [Abstract][Full Text] [Related]
23. Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial. Musinguzi N; Muwonge T; Thomas K; Baeten JM; Bangsberg DR; Haberer JE AIDS Behav; 2016 Nov; 20(11):2639-2643. PubMed ID: 26781865 [TBL] [Abstract][Full Text] [Related]
24. Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. Landovitz RJ; Beymer M; Kofron R; Amico KR; Psaros C; Bushman L; Anderson PL; Flynn R; Lee DP; Bolan RK; Jordan WC; Tseng CH; Dierst-Davies R; Rooney J; Wohl AR J Acquir Immune Defic Syndr; 2017 Dec; 76(5):501-511. PubMed ID: 28902074 [TBL] [Abstract][Full Text] [Related]
25. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force. Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746 [TBL] [Abstract][Full Text] [Related]
26. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K; Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265 [TBL] [Abstract][Full Text] [Related]
27. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ; Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303 [TBL] [Abstract][Full Text] [Related]
28. No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. Kapadia SN; Wu C; Mayer KH; Wilkin TJ; Amico KR; Landovitz RJ; Andrade A; Chen YQ; Chege W; McCauley M; Gulick RM; Schackman BR PLoS One; 2018; 13(12):e0206577. PubMed ID: 30586364 [TBL] [Abstract][Full Text] [Related]
29. Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities. Girometti N; Jones R; Levy J; McCormack S; Sullivan A; Barber TJ AIDS; 2016 Aug; 30(13):2131-3. PubMed ID: 27219131 [TBL] [Abstract][Full Text] [Related]
30. Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. Wahl A; Ho PT; Denton PW; Garrett KL; Hudgens MG; Swartz G; O'Neill C; Veronese F; Kashuba AD; Garcia JV Sci Rep; 2017 Feb; 7():41098. PubMed ID: 28145472 [TBL] [Abstract][Full Text] [Related]
31. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG; Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098 [TBL] [Abstract][Full Text] [Related]
32. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147 [TBL] [Abstract][Full Text] [Related]
34. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM; Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343 [TBL] [Abstract][Full Text] [Related]
35. Oral preexposure prophylaxis to prevent HIV infection: clinical and public health implications. Baker J; OʼHara KM JAAPA; 2014 Dec; 27(12):10-7. PubMed ID: 25390822 [TBL] [Abstract][Full Text] [Related]
36. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM; Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965 [TBL] [Abstract][Full Text] [Related]